Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 8 recruiting now early-phase tilt small index

Genitourinary Cancer: early-phase trial registry

8 of 16 indexed Genitourinary Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,060 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

16 US clinical trials · 8 currently recruiting · #1,060 of 28,707 conditions by registered trial count

Genitourinary Cancer: 16 US clinical trials tracked, 8 recruiting.

Genitourinary Cancer is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.

Enrollment posture brief

Registry condition genitourinary-cancer

OPEN 8 | RECR 50% | LATE 0 | EARLY 6 | RANK #1060 | SPON 3

Volume-matched condition peers

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Adolescent62.5%Alcohol Intoxication56.3%Genitourinary Cancer (this)50%AL Amyloidosis43.8%Allergy18.8%
Open-enrollment share among volume-matched conditions near Genitourinary Cancer

Genitourinary Cancer lists 8 open slots (50% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Genitourinary Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Genitourinary Cancer is recruiting above its size-band peers.

    8 of 16 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Genitourinary Cancer research.

    National Cancer Institute (NCI) accounts for 3 of 16 trials (18.8%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Typical Genitourinary Cancer enrolment sits around 100 participants.

    Median target enrolment is 100 among the 16 trials that report a genuine target (sentinel values excluded). 7 of those (43.8%) plan for fewer than 100 participants.

  4. Genitourinary Cancer research is mostly interventional.

    12 interventional and 4 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24

Open and recent trials

16 total, page 1 of 1

RECRUITING 1,100 participants

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

National Cancer Institute (NCI)

NCT04923178
RECRUITING 684 participants

Discharge Medication Use Post-Operatively in GU Cancer Patients

Wake Forest University Health Sciences

NCT06795087
RECRUITING Phase 1 210 participants

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

National Cancer Institute (NCI)

NCT06253520
RECRUITING 100 participants

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Washington University School of Medicine

NCT04354064
RECRUITING Phase 1 100 participants

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

National Cancer Institute (NCI)

NCT04235777
RECRUITING Phase 2 51 participants

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

University of California, Irvine

NCT06580002
RECRUITING NA 50 participants

Feasibility Study of CBCT for IGRT in Cancer Patients

Varian, a Siemens Healthineers Company

NCT06681233
RECRUITING Phase 2 24 participants

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

University of California, Irvine

NCT07447050
ACTIVE NOT RECRUITING 15,240 participants

Impact of COVID-19 on GU Disease

Icahn School of Medicine at Mount Sinai

NCT04761107
ACTIVE NOT RECRUITING NA 800 participants

Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)

Dana-Farber Cancer Institute

NCT05629065
ACTIVE NOT RECRUITING NA 156 participants

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

University of California, San Francisco

NCT02735252
ACTIVE NOT RECRUITING Phase 2 100 participants

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Dana-Farber Cancer Institute

NCT03333616
ACTIVE NOT RECRUITING NA 45 participants

An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer

Memorial Sloan Kettering Cancer Center

NCT03794635
ACTIVE NOT RECRUITING NA 32 participants

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2

Milton S. Hershey Medical Center

NCT06384417
COMPLETED Phase 2 60 participants

Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)

M.D. Anderson Cancer Center

NCT02060370
COMPLETED NA 14 participants

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning

Milton S. Hershey Medical Center

NCT06028152

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4

Top Sponsors

National Cancer Institute (NCI) 3 trials
Milton S. Hershey Medical Center 2 trials
Dana-Farber Cancer Institute 2 trials
University of California, Irvine 2 trials
Varian, a Siemens Healthineers Company 1 trials
Washington University School of Medicine 1 trials
Icahn School of Medicine at Mount Sinai 1 trials
M.D. Anderson Cancer Center 1 trials
University of California, San Francisco 1 trials
Memorial Sloan Kettering Cancer Center 1 trials

Named interventions

Most-linked intervention names on Genitourinary Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Riluzole Drug
2 trials
End-of-life conversation game called "Hello" Other
1 trials
Patient Nudge Letter and Share questionaire Other
1 trials
Clinician Nudge Email Other
1 trials
StrataNGS Device
1 trials
Systemic therapy Other
1 trials
Weekly 45 minute Sessions Behavioral
1 trials
Table Topics game Other
1 trials

US sites by state

Facility locations filed on Genitourinary Cancer trials. A trial with sites in several states counts in each.

California 5 trials
Pennsylvania 3 trials
Ohio 3 trials
Maryland 3 trials
Texas 2 trials
New York 2 trials
North Carolina 2 trials
Massachusetts 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Genitourinary Cancer page

16 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Genitourinary Cancer condition card totals 16 registered trials; most-linked intervention Riluzole; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.